BioSpace News Archive

Biogen’s 2022 fourth-quarter and full-year report comes the day after an additional warning on the company’s first Alzheimer’s drug came to light.

Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding.

Arrowhead Pharmaceuticals has gained full rights to ARO-PNPLA3, formerly JNJ-75220795, the company announced Wednesday.

Genome engineering company Replay and the MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.

Though advanced degrees are certainly helpful, they’re not always necessary to start and advance in a career in the life sciences. One just has to be willing to put in the work.

Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to USD 380 million, including USD 270 million in an upfront payment and up to USD 110 million in future conditional milestone payments.

Cytovation ASA announces that the first patient has been dosed in its Phase 2a study investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors.

Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit.

Immuron Limited invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.

Waters Corporation announced its financial results for the fourth quarter and full-year 2022.